Healthcare / BiotechnologyNasdaqGM
$1.57
-0.02 (-1.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-138.5M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$242M
P/E
N/A
•EV/EBITDA
N/A
•ROE
275.4%
↑Gross Margin
67.2%
↑Debt/Equity
0.66
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
+26.9%
FCF CAGR
—
FCF margin
-328.4%
FCF / Net income
-0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $42.2M · net income $168.0M · FCF $-138.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $42.2M | $42.2M | $26.4M | $257.2M | $211.0M | — | — | — | $0.00 | $1.6M | $189.5M | $30.0M | $31.1M | $2.8M | $1.9M |
| Net Income | $168.0M | $168.0M | $28.5M | $-237.9M | $-291.8M | $-287.1M | $132.2M | $89.8M | $-209.3M | $-238.2M | $-127.3M | $-223.3M | $-87.1M | $-53.6M | $-33.0M |
| EBITDA | $-170.2M | $-170.2M | $-199.4M | $-193.9M | $-255.6M | $-260.4M | $159.2M | $111.0M | $-201.2M | $-228.7M | $-112.9M | $-217.2M | $-64.0M | $-35.6M | $-38.3M |
| EPS | — | — | 0.25 | -2.53 | -3.76 | -3.81 | 1.62 | 1.23 | -3.22 | -4.48 | — | — | — | — | — |
| Gross Margin | 67.2% | 67.2% | 66.9% | 38.2% | 66.8% | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -429.5% | -429.5% | -756.6% | -79.0% | -121.7% | — | — | — | — | -14918.8% | -61.2% | -729.2% | -207.9% | -1308.4% | -2028.3% |
| Net Margin | 398.4% | 398.4% | 108.0% | -92.5% | -138.2% | — | — | — | — | -15306.6% | -67.2% | -743.2% | -280.1% | -1949.7% | -1738.7% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.66 | 0.66 | -2.04 | -2.49 | -3.50 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.56 | 1.56 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-138.5M | $-138.5M | $-20.4M | $-174.9M | $-241.1M | $-38.7M | $146.9M | $26.5M | $-160.1M | $-204.9M | $-259.1M | — | — | — | — |
| Returns | |||||||||||||||
| ROE | 275.4% | 275.4% | -21.6% | 123.0% | 212.3% | -293.8% | 47.1% | 85.4% | 542.5% | -780.0% | -620.3% | 3596.9% | -130.4% | 55.2% | — |
| Valuation | |||||||||||||||
| P/E | — | — | 6.64 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 3.12 | 3.12 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | 59.8% | 59.8% | -89.7% | 21.9% | — | — | — | — | -100.0% | -99.2% | 530.7% | -3.4% | 1030.7% | 44.9% | — |
| EPS Growth | — | — | 109.9% | 32.7% | — | -335.2% | 31.7% | 138.2% | 28.1% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+101.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.25 → n/d
Residual
+101.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.